Beta-arrestin-biased ligands at the AT1R: A novel approach to the treatment of acute heart failure

Drug Discovery Today: Therapeutic Strategies

Volumn 9, Issue 4, 2012, Pages

  Violin, Jonathan D ^a   Soergel, David G ^a   Lark, Michael W ^a  

^a TREVENA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ARRESTIN; BETA ARRESTIN BIASED LIGAND; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LIGAND; PLACEBO; TRV 027; TRV 120023; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; APOPTOSIS; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEMODYNAMICS; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; TREATMENT INDICATION; VASOCONSTRICTION;

EID: 84900816342     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2014.01.001     Document Type: Review

References (34)

1. K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, and P.A. Poole-Wilson et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology, Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail 10 2008 933 989
2. L.A. Allen, and C.M. O'Connor Management of acute decompensated heart failure CMAJ 176 2007 797 805
3. M. Gheorghiade, F. Zannad, G. Sopko, L. Klein, I.L. Pina, and M.A. Konstam et al. Acute heart failure syndromes: current state and framework for future research Circulation 112 2005 3958 3968
4. R.R. Ruffolo Jr., G.Z. Feuerstein, and E.H. Ohlstein Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure Am J Hypertens 11 Pt 2 1998 9S 14S
5. N.A. Awan, and D.T. Mason Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure Am Heart J 131 1996 177 185
6. S.M. Jafri The effects of beta blockers on morbidity and mortality in heart failure Heart Fail Rev 9 2004 115 121
7. B. Pitt Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn? Am J Hypertens 15 Pt 2 2002 22S 27S
8. S.M. Silvers, J.M. Howell, J.M. Kosowsky, I.C. Rokos, and A.S. Jagoda Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes Ann Emerg Med 49 2007 627 669
9. K. Swedberg, P. Held, J. Kjekshus, K. Rasmussen, L. Ryden, and H. Wedel et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med 327 1992 678 684
10. V.J. Dzau Cardiac renin-angiotensin system. Molecular and functional aspects Am J Med 84 3A 1988 22 27
11. G.P. Guthrie Jr. Angiotensin receptors: physiology and pharmacology Clin Cardiol 18 Suppl 3, III 1995 29 34
12. J.D. Violin, and R.J. Lefkowitz Beta-arrestin-biased ligands at seven-transmembrane receptors Trends Pharmacol Sci 28 2007 416 422
13. T. Kenakin New concepts in pharmacological efficacy at 7TM receptors Br J Pharmacol 2012
14. K. Rakesh, B. Yoo, I.M. Kim, N. Salazar, K.S. Kim, and H.A. Rockman beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress Sci Signal 3 2010 ra46
15. K. Rajagopal, E.J. Whalen, J.D. Violin, J.A. Stiber, P.B. Rosenberg, and R.T. Premont et al. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes Proc Natl Acad Sci U S A 103 2006 16284 16289
16. S. Ahn, J. Kim, M.R. Hara, X.R. Ren, and R.J. Lefkowitz {beta}-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation J Biol Chem 284 2009 8855 8865
17. H. Wei, S. Ahn, S.K. Shenoy, S.S. Karnik, L. Hunyady, and L.M. Luttrell et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 Proc Natl Acad Sci U S A 100 2003 10782 10787
18. R.H. Oakley, S.A. Laporte, J.A. Holt, M.G. Caron, and L.S. Barak Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors J Biol Chem 275 2000 17201 17210
19. J.D. Violin, S.M. Dewire, W.G. Barnes, and R.J. Lefkowitz G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics J Biol Chem 281 2006 36411 36419
20. J. Zhang, S.S. Ferguson, L.S. Barak, L. Menard, and M.G. Caron Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization J Biol Chem 271 1996 18302 18305
21. L. Hunyady, and K.J. Catt Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II Mol Endocrinol 20 2006 953 970
22. S.M. DeWire, S. Ahn, R.J. Lefkowitz, and S.K. Shenoy Beta-arrestins and cell signaling Annu Rev Physiol 69 2007 483 510
23. J.L. Hansen, M. Aplin, J.T. Hansen, G.L. Christensen, M.M. Bonde, and M. Schneider et al. The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation Eur J Pharmacol 590 1-3 2008 255 263
24. S.M. DeWire, J. Kim, E.J. Whalen, S. Ahn, M. Chen, and R.J. Lefkowitz Beta-arrestin-mediated signaling regulates protein synthesis J Biol Chem 283 16 2008 10611 10620
25. D.L. Hunton, W.G. Barnes, J. Kim, X.R. Ren, J.D. Violin, and E. Reiter et al. Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis Mol Pharmacol 67 4 2005 1229 1236
26. J.D. Violin, S.M. DeWire, D. Yamashita, D.H. Rominger, L. Nguyen, and K. Schiller et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance J Pharmacol Exp Ther 335 3 2010 572 579
27. K.S. Kim, D. Abraham, B. Williams, J.D. Violin, L. Mao, and H.A. Rockman beta-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury Am J Physiol Heart Circ Physiol 303 8 2012 H1001 H1010
28. M.M. Monasky, D.M. Taglieri, M. Henze, C.M. Warren, M.S. Utter, and D.G. Soergel et al. The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium Am J Physiol Heart Circ Physiol 2013
29. W.T. Abraham, K.F. Adams, G.C. Fonarow, M.R. Costanzo, R.L. Berkowitz, and T.H. LeJemtel et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 1 2005 57 64
30. M.S. Cuffe, R.M. Califf, K.F. Adams Jr., R. Benza, R. Bourge, and W.S. Colucci et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 12 2002 1541 1547
31. J.R. Teerlink Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure Am Heart J 145 2 Suppl 2003 S26 S33
32. G. Boerrigter, M.W. Lark, E.J. Whalen, D.G. Soergel, J.D. Violin, and J.C. Burnett Jr. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure Circ Heart Fail 4 6 2011 770 778
33. G. Boerrigter, D.G. Soergel, J.D. Violin, M.W. Lark, and J.C. Burnett Jr. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure Circ Heart Fail 2012
34. D.G. Soergel, R.A. Subach, C.L. Cowan, J.D. Violin, and M.W. Lark First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers J Clin Pharmacol 53 9 2013 892 899